UBS Group AG Raises Stake in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• UBS Group AG increased its stake in Arrowhead Pharmaceuticals by 7.5% in Q4 to 987,287 shares (about 0.73% of the company), valued at roughly $65.55 million.
• Arrowhead reported quarterly revenue of $264.03 million—up an extraordinary 10,461% year-over-year—but missed EPS expectations ($0.22 vs. $0.60); the stock trades near its 52-week high (~$76) with a market cap of $10.7 billion and a PE of ~49.9.
• Insiders sold 33,095 shares (~$2.33 million) in the last 90 days under pre-arranged 10b5-1 plans, institutions own 62.61% of the stock, and analysts' consensus is a Moderate Buy with an average price target of $84.20.

UBS Group AG increased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 7.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 987,287 shares of the biotechnology company's stock after purchasing an additional 69,104 shares during the period. UBS Group AG owned 0.73% of Arrowhead Pharmaceuticals worth $65,546,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. iSAM Funds UK Ltd purchased a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth $29,000. First Horizon Corp purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth $32,000. Salomon & Ludwin LLC purchased a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth $34,000. WPG Advisers LLC boosted its holdings in Arrowhead Pharmaceuticals by 384.8% in the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 431 shares during the period. Finally, Federated Hermes Inc. purchased a new position in Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $52,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Price Performance

Shares of Arrowhead Pharmaceuticals stock opened at $76.39 on Tuesday. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29. The company's 50-day moving average price is $63.47 and its two-hundred day moving average price is $59.52. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $12.44 and a 52 week high of $76.76. The stock has a market cap of $10.70 billion, a PE ratio of 49.93 and a beta of 1.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The business had revenue of $264.03 million during the quarter, compared to the consensus estimate of $225.66 million. During the same quarter last year, the firm posted ($1.39) earnings per share. Arrowhead Pharmaceuticals's revenue was up 10461.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ARWR shares. Weiss Ratings upgraded Arrowhead Pharmaceuticals from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday, February 6th. Piper Sandler restated an "overweight" rating and set a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. HC Wainwright reissued a "buy" rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, March 25th. JPMorgan Chase & Co. started coverage on Arrowhead Pharmaceuticals in a research note on Friday. They issued an "overweight" rating and a $88.00 target price on the stock. Finally, Morgan Stanley raised Arrowhead Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $78.00 to $100.00 in a report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $84.20.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 10,000 shares of the company's stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the transaction, the insider owned 226,958 shares of the company's stock, valued at approximately $17,021,850. This represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the company's stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total value of $934,328.25. Following the completion of the transaction, the chief financial officer directly owned 162,905 shares in the company, valued at $11,623,271.75. This represents a 7.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 33,095 shares of company stock worth $2,326,228 in the last ninety days. 3.60% of the stock is owned by corporate insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.